businesspress24.com - Daxor Announces Placement of BVA-100 Blood Volume Analyzer at North Alabama Radiopharmacy
 

Daxor Announces Placement of BVA-100 Blood Volume Analyzer at North Alabama Radiopharmacy

ID: 1132523

(firmenpresse) - NEW YORK, NY -- (Marketwire) -- 07/12/12 -- Daxor Corporation (NYSE MKT: DXR) (NYSE Amex: DXR), an investment company with medical instrumentation and biotechnology operations, today announced the placement of Daxor's BVA-100 Blood Volume Analyzer at North Alabama Radiopharmacy.

North Alabama Radiopharmacy (NARP) is an independently owned nuclear pharmacy founded in 1990 to service over 25 hospitals and clinics throughout North Alabama and Southern Tennessee. They supply the materials, specialized equipment and clinical support for the diagnostic and therapy procedures utilizing radiopharmaceuticals. Their C.L.I.A. approved radiobioassay laboratory is the only one of its kind in the State of Alabama and provides many hospitals an opportunity to utilize these essential medical services.

The pharmacist and technicians at NARP and their subsidiary company, North Alabama Infusion and Compounding, are committed to providing the best possible solutions and quality care to their customers and patients. The Daxor BVA blood volume analyzer installed at NARP is the first in the State of Alabama and will help develop even better medical analyses and outcomes for patients.

The president of North Alabama Radiopharmacy, Max Akin, said, "I view this as an opportunity to improve patient outcomes for those associated with poor prognosis. I believe that this advanced testing method will become an essential service in treating heart failure and other life threatening conditions."

Daxor Corporation manufactures and markets the BVA-100, which is used in conjunction with Volumex, Daxor's single use diagnostic kit. For more information regarding Daxor Corporation's Blood Volume Analyzer BVA-100, visit Daxor's website at .



Daxor Contact Information:

Richard Dunn
Director of Operations
212-330-8502


Diane Meegan
Investor Relations
212-330-8512




Themen in dieser Pressemitteilung:


Unternehmensinformation / Kurzprofil:



Leseranfragen:



PresseKontakt / Agentur:



drucken  als PDF  an Freund senden  AVI BioPharma Announces Corporate Name Change to Sarepta Therapeutics and Stock Ticker Symbol Change to Critical Outcome Technologies Inc. Strengthens Board With New Director
Bereitgestellt von Benutzer: MARKETWIRE
Datum: 12.07.2012 - 06:30 Uhr
Sprache: Deutsch
News-ID 1132523
Anzahl Zeichen: 0

contact information:
Contact person:
Town:

NEW YORK, NY


Phone:

Kategorie:

Biotech


Anmerkungen:


Diese Pressemitteilung wurde bisher 131 mal aufgerufen.


Die Pressemitteilung mit dem Titel:
"Daxor Announces Placement of BVA-100 Blood Volume Analyzer at North Alabama Radiopharmacy
"
steht unter der journalistisch-redaktionellen Verantwortung von

Daxor Corp. (Nachricht senden)

Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).


Alle Meldungen von Daxor Corp.



 

Who is online

All members: 10 567
Register today: 2
Register yesterday: 0
Members online: 0
Guests online: 118


Don't have an account yet? You can create one. As registered user you have some advantages like theme manager, comments configuration and post comments with your name.